Ludwig Cancer Research engages leading scientists and clinicians in an integrated effort to understand and confront the challenge of cancer. The Oxford Branch is based at the University of Oxford, UK and benefits from excellent links with the global Ludwig Cancer Research and local Oxford research communities.
Ludwig Oxford Branch researchers are investigating all stages of cancer, from the risk of disease through to new treatment opportunities. Our research groups are interested in the signalling pathways that influence cancer initiation and progression, with a focus on infection, inflammation and cancer epigenetics. We aim to advance cancer prevention, early diagnosis and effective treatment. Find out more about the Ludwig Oxford research groups.
News
Switching on cancer’s viral alarm system
19 May, 2026
Publications
EVOLVE-HBV: A cross-sectional study of HBV seroepidemiology in a rural population in South Africa
Journal article
Anderson M. et al, (2026), International Journal of Infectious Diseases, 171, 108998 - 108998
Body Composition Changes in Children Living With HIV Initiated on Dolutegravir or Protease Inhibitors in the CHAPAS-4 Trial
Journal article
Natukunda E. et al, (2026), Pediatric Infectious Disease Journal, 45, 768 - 775
TTC7A deficiency: A retrospective international study on treatment and outcomes from the Inborn Errors Working Party of EBMT.
Journal article
Prunotto G. et al, (2026), Journal of human immunity, 2
Seminars
Chemical Approaches to Decoding Epigenetics
Thursday, 3 September 2026, 11am to 12pm
Speaker(s): Prof Xiang David Li
Epigenomic Variation Reveals the Hijacking of Transposable Elements in Cancer
Friday, 4 September 2026, 11am to 12pm
Speaker(s): Dr Mathieu Lupien
conference
